Buscar
Glaukos Corp
GKOSAñadir a la lista de seguimiento
153.580USD
+1.525+1.00%
Cierre 07-24 16:00（ET）Cotizaciones retrasadas 15 min
9.02BCap. mercado
PérdidaP/E TTM
Más Datos de Glaukos Corp Compañía
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Información de Glaukos Corp
Símbolo de cotizaciónGKOS
Nombre de la empresaGlaukos Corp
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoBurns (Thomas William)
Número de empleados995
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 25
Dirección1 Glaukos Way
CiudadALISO VIEJO
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal92656
Teléfono19493679600
Sitio Webhttps://www.glaukos.com
Símbolo de cotizaciónGKOS
Fecha de salida a bolsaJun 25, 2015
Director ejecutivoBurns (Thomas William)
Ejecutivos de Glaukos Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Glaukos Corp?
Los cinco principales accionistas de Glaukos Corp son: Mr. Thomas William Burns
¿Cuántas instituciones poseen acciones de Glaukos Corp (GKOS)?
A fecha de 2026Q1, 702 instituciones poseen acciones de Glaukos Corp, con un valor de mercado combinado de aproximadamente 59.35M, lo que representa el 101.04% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2784097.00.
¿Cuál es la mayor fuente de ganancias de Glaukos Corp?
El 2026Q1, el segmento empresarial Glaucoma generó la ganancia más alta para Glaukos Corp, ascendiendo a 421.07M y representando el 82.98% de la ganancia total.